TY - JOUR
T1 - Plasma TIMP-1 and CEA as markers for detection of primary colorectal cancer
T2 - a prospective validation study including symptomatic and non-symptomatic individuals
AU - Christensen, Ib Jarle
AU - Brünner, Nils
AU - Dowell, Barry
AU - Davis, Gerard
AU - Nielsen, Hans Jørgen
AU - Newstead, Graham
AU - King, Denis
N1 - Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Background/Aim: The combination of plasma tissue inhibitor of metalloproteinases-1 (1) and CEA has been shown to have utility in early detection of colorectal cancer (2). A prospective study was performed to validate previous findings. Patients and Methods: Individuals undergoing large bowel endoscopy were prospectively included (N=1965). Baseline data and co-morbidity were recorded. The primary end-point was the detection of CRC. Plasma was obtained before endoscopy and TIMP-1 and CEA levels were determined using an automated analysis platform when all samples were collected. Results: CRC was detected in 32 individuals, 24 with colonic cancer (CC) and 8 with rectal cancer (RC). Other findings were 265 with adenomas and 889 with non-neoplastic pathology. The biomarker levels were elevated in plasma from patients with CRC, but also from patients with various co-morbidities compared to individuals without any findings at endoscopy. Univariate analysis demonstrated that both markers were significant predictors of CRC. The odds ratios (OR) for an elevated TIMP-1 level for the detection of CRC was 6.2 [95% confidence interval (CI)=3.1-13.0, p<0.0001] and for an elevated CEA level was 2.4 (95% CI=1.9-2.9, p<0.0001). A subset analysis with CC as the end-point showed an OR for TIMP-1 of 7.0 (95% CI=3.2-15.3, p<0.0001). Multivariable analysis including TIMP-1, CEA and age resulted in an OR for TIMP-1 of 2.0 (95% CI=0.7- 5.2, p=0.078) and for CEA the OR was 2.2 (95% CI=1.8- 2.8, p<0.0001). Conclusion: This prospective study validates a previous study testing the detection of CRC based on TIMP-1 and CEA levels (3).
AB - Background/Aim: The combination of plasma tissue inhibitor of metalloproteinases-1 (1) and CEA has been shown to have utility in early detection of colorectal cancer (2). A prospective study was performed to validate previous findings. Patients and Methods: Individuals undergoing large bowel endoscopy were prospectively included (N=1965). Baseline data and co-morbidity were recorded. The primary end-point was the detection of CRC. Plasma was obtained before endoscopy and TIMP-1 and CEA levels were determined using an automated analysis platform when all samples were collected. Results: CRC was detected in 32 individuals, 24 with colonic cancer (CC) and 8 with rectal cancer (RC). Other findings were 265 with adenomas and 889 with non-neoplastic pathology. The biomarker levels were elevated in plasma from patients with CRC, but also from patients with various co-morbidities compared to individuals without any findings at endoscopy. Univariate analysis demonstrated that both markers were significant predictors of CRC. The odds ratios (OR) for an elevated TIMP-1 level for the detection of CRC was 6.2 [95% confidence interval (CI)=3.1-13.0, p<0.0001] and for an elevated CEA level was 2.4 (95% CI=1.9-2.9, p<0.0001). A subset analysis with CC as the end-point showed an OR for TIMP-1 of 7.0 (95% CI=3.2-15.3, p<0.0001). Multivariable analysis including TIMP-1, CEA and age resulted in an OR for TIMP-1 of 2.0 (95% CI=0.7- 5.2, p=0.078) and for CEA the OR was 2.2 (95% CI=1.8- 2.8, p<0.0001). Conclusion: This prospective study validates a previous study testing the detection of CRC based on TIMP-1 and CEA levels (3).
M3 - Journal article
C2 - 26254391
SN - 0250-7005
VL - 35
SP - 4935
EP - 4941
JO - Anticancer Research
JF - Anticancer Research
IS - 9
ER -
